Anteris Technologies Global Corp. (AVR) Stock

Anteris Technologies Global Corp. (AVR) is a Healthcare stock trading at $9.78 (as of 2026-06-18), with a market capitalization of $871.21M and a trailing P/E of -4.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Anteris Technologies Global Corp. develops and commercializes medical devices for structural heart conditions, including products for aortic stenosis. Its portfolio includes the DurAVR transcatheter heart valve system, the ADAPT anti-calcification tissue preparation, and the ComASUR delivery system, which are intended for use in heart valve procedures.

Valuation — source: SEC EDGAR (first-party)
Price	$9.78
Market Cap	$871.21M
P/E Ratio	-4.1
EV / EBITDA	-6.4
Price / Book	3.20
Price / Sales	481.19
DCF Value (model)	$-13.84
DCF Upside vs Price	-241.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.91M
Net Margin	-4921.3%
Return on Equity	-34.2%
Current Ratio	20.93
Revenue Growth (YoY)	-29.2%
EPS Growth (YoY)	-30.7%
FCF Growth (YoY)	25.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-11.70 (distress)

Valuation vs Sector & Industry
Stock P/E	-4.1
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-119.7%
vs Industry	-113.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	L1 Capital Pty Ltd ($43.23M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Wayne Geoffrey Paterson
Employees	136
Country	AU
IPO Date	2024-12-13

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.